Publicaciones en las que colabora con Manuel Crespo Hernández (31)

2022

  1. Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients

    Frontiers in Pharmacology, Vol. 13

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  3. Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control

    The Journal of infectious diseases, Vol. 225, Núm. 6, pp. 1040-1049

  4. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Clinical characteristics, aetiology and mortality/recurrence risk factors of acute cholangitis in patients with and without biliary stent

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 39, Núm. 9, pp. 445-450

  3. The benefits and safety of oral sequential antibiotic therapy in non-complicated and complicated Staphylococcus aureus bacteremia

    International Journal of Infectious Diseases, Vol. 102, pp. 554-560

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  2. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

2019

  1. Moving beyond unsolicited consultation: Additional impact of a structured intervention on mortality in Staphylococcus aureus bacteraemia

    Journal of Antimicrobial Chemotherapy, Vol. 74, Núm. 4, pp. 1101-1107

  2. Short- versus long-course therapy in gram-negative bacilli bloodstream infections

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 38, Núm. 5, pp. 851-857

  3. Validation of a clinical decision tree to predict if a patient has a bacteraemia due to a β-lactamase producing organism

    Infectious Diseases, Vol. 51, Núm. 1, pp. 32-37

2018

  1. Clinical and microbiological characteristics of unusual manifestations of invasive pneumococcal disease

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 5, pp. 284-289

  2. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 11, pp. 3170-3175

2017

  1. Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: Potential role as a biomarker of HIV replication

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 11, pp. 3159-3162

  2. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

  3. Sofosbuvir and daclatasvir in mono-and HIV-coinfected patients with recurrent hepatitis C After liver transplant

    Annals of Hepatology, Vol. 16, Núm. 1, pp. 86-93

2016

  1. Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: A randomized trial

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 5, pp. 1346-1351

2015

  1. Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: A randomized clinical trial

    Clinical Infectious Diseases, Vol. 60, Núm. 5, pp. 811-820

  2. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784